Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares")

Q: What does CUSIP 002942100 represent in this 13F holders report?

CUSIP 002942100 is the security identifier for 002942100 - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") used to aggregate holder disclosures.

Q: How many institutions held 002942100 - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") in Q4 2025?

3 institutional investors reported 002942100 - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 002942100

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, par value $0.00001 per share (the "Shares")
Shares outstanding: 21,303,054
Total 13F shares: 2,164,933
Share change: +251,068
Total reported value: $28,414,746
Price per share: $13.12
Number of holders: 3
Value change: +$3,295,267
Number of buys: 2
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 002942100?
CUSIP 002942100 identifies 002942100 - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026

Recent filing periods for CUSIP 002942100:

Q1 2026 Q4 2025

Top shareholders of 002942100 - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
CITADEL ADVISORS LLC	13F 13D/G	Company · Kenneth Griffin	5.6% from 13D/G	1,359,883	$18,072,846	—	30 Sep 2025	13F 13D/G
STATE STREET CORP	13F	Company	0.44%	93,005	$1,236,036	—	30 Sep 2025	13F

Institutional Holders of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") as of Q4 2025

As of 31 Dec 2025, Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") was held by 3 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,164,933 shares. The largest 3 holders included CITADEL ADVISORS LLC, VANGUARD GROUP INC, and STATE STREET CORP. This page lists 3 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q4 2025 Across Filers

Q4 2025 holders

Holder diff

Investor	Q4 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.